Tris Pharma to Showcase Encore Phase 3 Data Supporting Continued Progress in Acute Pain Treatment at ASRA 2026 Meeting in Phoenix

Encore data to be presented demonstrating that cebranopadol displays significant and sustained pain reduction with a distinguished safety ...